Levemir gets positive EMA/CHMP opinion for extended use in children

26 June 2015

Danish diabetes care giant Novo Nordisk (NOV: N) today announced that the European Medicines agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expanded use of Levemir(insulin detemir) in children with diabetes as young as one year old.

There are an estimated 497,100 children living with type 1 diabetes globally and incidence is increasing in many countries. Young children with type 1 diabetes can be difficult to treat as their needs are in constant flux during growth and development2, with children aged six and under at greatest risk of severe hypoglycaemia and acute diabetes complications3.

Levemir, a long-acting basal insulin for the treatment of diabetes, was launched in 2004 and is available in 90 countries. First-quarter 2015 sales of Levemir increased by 31% year-on-year to 4.07 billion kroner ($617 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK